BMP-2 Treatment Results in Different Complication Trends in ASD Patients

Study data finds similar outcomes, but distinct trends

Peter Pollack

Patients with adult spinal deformity (ASD) who are treated with recombinant human bone morphogenetic protein-2 (BMP-2) are likely to see a different—but not necessarily more beneficial—pattern of complications than those treated without BMP-2, according to research presented at the 2013 annual meeting of the North American Spine Society (NASS).

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement